Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Molecular mechanism of WW-domain binding protein-2 coactivation function in estrogen receptor signaling.

Buffa L, Saeed AM, Nawaz Z.

IUBMB Life. 2013 Jan;65(1):76-84. doi: 10.1002/iub.1105. Epub 2012 Dec 10.

2.

WW domain binding protein-2, an E6-associated protein interacting protein, acts as a coactivator of estrogen and progesterone receptors.

Dhananjayan SC, Ramamoorthy S, Khan OY, Ismail A, Sun J, Slingerland J, O'Malley BW, Nawaz Z.

Mol Endocrinol. 2006 Oct;20(10):2343-54. Epub 2006 Jun 13.

PMID:
16772533
3.

MICoA, a novel metastasis-associated protein 1 (MTA1) interacting protein coactivator, regulates estrogen receptor-alpha transactivation functions.

Mishra SK, Mazumdar A, Vadlamudi RK, Li F, Wang RA, Yu W, Jordan VC, Santen RJ, Kumar R.

J Biol Chem. 2003 May 23;278(21):19209-19. Epub 2003 Mar 14.

4.

Stimulatory cross-talk between NFAT3 and estrogen receptor in breast cancer cells.

Zhang H, Xie X, Zhu X, Zhu J, Hao C, Lu Q, Ding L, Liu Y, Zhou L, Liu Y, Huang C, Wen C, Ye Q.

J Biol Chem. 2005 Dec 30;280(52):43188-97. Epub 2005 Oct 11.

5.

Metastasis-associated protein 1 interacts with NRIF3, an estrogen-inducible nuclear receptor coregulator.

Talukder AH, Gururaj A, Mishra SK, Vadlamudi RK, Kumar R.

Mol Cell Biol. 2004 Aug;24(15):6581-91.

6.
7.

p300 is a component of an estrogen receptor coactivator complex.

Hanstein B, Eckner R, DiRenzo J, Halachmi S, Liu H, Searcy B, Kurokawa R, Brown M.

Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11540-5.

8.

Different classes of coactivators recognize distinct but overlapping binding sites on the estrogen receptor ligand binding domain.

Eng FC, Barsalou A, Akutsu N, Mercier I, Zechel C, Mader S, White JH.

J Biol Chem. 1998 Oct 23;273(43):28371-7.

9.

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.

Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R.

J Natl Cancer Inst. 2004 Jun 16;96(12):926-35.

PMID:
15199112
10.

Estrogen-occupied estrogen receptor represses cyclin G2 gene expression and recruits a repressor complex at the cyclin G2 promoter.

Stossi F, Likhite VS, Katzenellenbogen JA, Katzenellenbogen BS.

J Biol Chem. 2006 Jun 16;281(24):16272-8. Epub 2006 Apr 10.

15.

p33ING1b and estrogen receptor (ER) alpha.

Toyama T, Iwase H.

Breast Cancer. 2004;11(1):33-7. Review.

PMID:
14718790
16.

Genomic analyses of transcription factor binding, histone acetylation, and gene expression reveal mechanistically distinct classes of estrogen-regulated promoters.

Kininis M, Chen BS, Diehl AG, Isaacs GD, Zhang T, Siepel AC, Clark AG, Kraus WL.

Mol Cell Biol. 2007 Jul;27(14):5090-104. Epub 2007 May 21.

18.

Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology.

Katzenellenbogen BS, Choi I, Delage-Mourroux R, Ediger TR, Martini PG, Montano M, Sun J, Weis K, Katzenellenbogen JA.

J Steroid Biochem Mol Biol. 2000 Nov 30;74(5):279-85. Review.

PMID:
11162936
19.

CCDC62/ERAP75 functions as a coactivator to enhance estrogen receptor beta-mediated transactivation and target gene expression in prostate cancer cells.

Chen M, Ni J, Chang HC, Lin CY, Muyan M, Yeh S.

Carcinogenesis. 2009 May;30(5):841-50. doi: 10.1093/carcin/bgn288. Epub 2009 Jan 6.

PMID:
19126643
20.

Flightless I (Drosophila) homolog facilitates chromatin accessibility of the estrogen receptor α target genes in MCF-7 breast cancer cells.

Jeong KW.

Biochem Biophys Res Commun. 2014 Apr 4;446(2):608-13. doi: 10.1016/j.bbrc.2014.03.011. Epub 2014 Mar 12.

PMID:
24632205

Supplemental Content

Support Center